CD4 and neoplasm: Daclizumab is used to treat acute-graft rejection by targeting CD25-expressing effector T cells,34 but it has also been shown to effectively deplete CD4+ regulatory T cells in humans, improving immune responses after tumor-antigen vaccination in patients with metastatic breast cancer.35